AXL and hepatocellular carcinoma: Here, our data collectively describe an underlying mechanism and offer additional proof-of-concept to demonstrate that targeting AXL could be a therapeutic opportunity to bolster immunotherapy in HCC patients who are refractory to first-line TKI treatment.